To amend the Federal Food, Drug, and Cosmetic Act to establish a time-limited conditional approval pathway, subject to specific obligations, for certain drugs and biological products, and for other purposes.
About This Bill
Committee
Latest Action · October 4, 2024
Referred to the House Committee on Energy and Commerce.